IDEA Pharma and SAI MedPartners released the inaugural China Pharmaceutical Innovation and Invention Index, ranking Hengrui and BeOne at the top for invention and innovation. The report evaluated research spending, international patent filings, and regulatory approvals to score 50 Chinese companies. Authors said the index aims to clarify which domestic players are generating novel science and successfully translating it into new medicines. The ranking will be used by global pharma executives and investors to identify collaboration and licensing targets. The analysis underlines China’s rising role in global drug development and provides a benchmarking tool for partnerships, M&A, and R&D investment decisions.